Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)
Interim Results from Pivotal Neoadjuvant/Adjuvant Phase 3 KEYNOTE-522 Trial Presented for the First Time at ESMO 2019 Congress During Presidential Symposium
As Previously Announced, KEYTRUDA Plus Chemotherapy Has Been Granted Breakthrough Therapy Designation by US FDA for Neoadjuvant Treatment of High-Risk, Early-Stage TNBC
KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from the pivotal neoadjuvant/adjuvant Phase 3 KEYNOTE-522 trial in patients with early-stage triple-negative breast cancer (TNBC). The trial investigated a regimen of neoadjuvant KEYTRUDA, Merck’s anti-PD-1 therapy, plus chemotherapy, followed by adjuvant KEYTRUDA as monotherapy (the KEYTRUDA regimen) compared with a regimen of neoadjuvant chemotherapy followed by adjuvant placebo (the chemotherapy-placebo regimen).
Media:
Pamela Eisele
(267) 305-3558
Claire Mulhearn
(908) 200-1889
Investors:
Peter Dannenbaum
(908) 740-1037
Courtney Ronaldo
(908) 740-6132
